<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016804</url>
  </required_header>
  <id_info>
    <org_study_id>SC-10-ATG-12-04</org_study_id>
    <nct_id>NCT05016804</nct_id>
  </id_info>
  <brief_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis</brief_title>
  <official_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Foundation for Orthopaedics and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Foundation for Orthopaedics and Regenerative Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic&#xD;
      adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that stem cell treatment is safe and efficacious for the treatment of&#xD;
      Systemic Sclerosis. Patients with Systemic Sclerosis will receive a single intravenous&#xD;
      infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. The&#xD;
      total dose will be 100 million cells. Patients will be evaluated within one month pre&#xD;
      treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>Clinical monitoring of possible adverse events or complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: skin score</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>It will be completed for each follow up point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Forced vital capacity (FVC)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>It will be completed for each follow up point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of 100 million cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloRx</intervention_name>
    <description>cultured allogeneic adult umbilical cord derived mesenchymal stem cells</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Systemic Sclerosis&#xD;
&#xD;
          -  Understanding and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Chronic multisystem organ failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinically significant Abnormalities on pre-treatment laboratory evaluation&#xD;
&#xD;
          -  Medical condition that would (based on the opinion of the investigator) compromise&#xD;
             patient's safety.&#xD;
&#xD;
          -  Continued drug abuse&#xD;
&#xD;
          -  Pre-menopausal women not using contraception&#xD;
&#xD;
          -  Previous organ transplant&#xD;
&#xD;
          -  Hypersensitivity to sulfur&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Prodromos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Foundation for Orthopaedics and Regenerative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Surgical Associates Center</name>
      <address>
        <city>St. John's</city>
        <country>Antigua and Barbuda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadwick Prodromos, M.D.</last_name>
      <phone>8476996810</phone>
      <email>research@ismoc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Antigua and Barbuda</country>
  </location_countries>
  <reference>
    <citation>Kaldas M, Khanna PP, Furst DE, Clements PJ, Kee Wong W, Seibold JR, Postlethwaite AE, Khanna D; investigators of the human recombinant relaxin and oral bovine collagen clinical trials. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford). 2009 Sep;48(9):1143-6. doi: 10.1093/rheumatology/kep202. Epub 2009 Jul 14.</citation>
    <PMID>19605370</PMID>
  </reference>
  <reference>
    <citation>Granel B, Daumas A, Jouve E, Harl√© JR, Nguyen PS, Chabannon C, Colavolpe N, Reynier JC, Truillet R, Mallet S, Baiada A, Casanova D, Giraudo L, Arnaud L, Veran J, Sabatier F, Magalon G. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015 Dec;74(12):2175-82. doi: 10.1136/annrheumdis-2014-205681. Epub 2014 Aug 11.</citation>
    <PMID>25114060</PMID>
  </reference>
  <reference>
    <citation>Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019 Jan 7;21(1):7. doi: 10.1186/s13075-018-1792-8.</citation>
    <PMID>30616671</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>stem cell treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

